Please assess the completion status of the following clinical trial:

Trial Title: REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MF-CTCL stage IA or IB at enrolment as per ISCL/EORTC revision to the MF and Sézary syndrome classification and MF stage should have never met the criteria for stage IIA or higher in the patient medical history~* Lesions cover less than 80% of BSA~* Age ≥ 18~* ECOG/WHO performance status 0-2~Exclusion Criteria:~* Previous treatment with CL gel~* Concurrent or planned local or systemic anti-CTCL therapy~* Prior treatment with antihistamines or narrow band UV-B or PUVA therapy one week before enrolment, or systemic corticosteroids or radiotherapy in the last 4 weeks before enrolment~* Prior treatment with topical steroids in the patch test area (upper back) one week before enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adult patients with early stage MF-CTCL (stage IA-IB) (Type: EXPERIMENTAL): Patients are treated with Chlormethine gel (CL) gel. In case of any skin drug reaction, allergic test will be carried out. Patients not allergic to CL gel will continue at reduced application frequency, with the addition of topical steroid if necessary.

Based on this trial design, predict the completion outcome and termination type (if applicable).